611 related articles for article (PubMed ID: 19136637)
1. Pharmacological characterization of ATPM [(-)-3-aminothiazolo[5,4-b]-N-cyclopropylmethylmorphinan hydrochloride], a novel mixed kappa-agonist and mu-agonist/-antagonist that attenuates morphine antinociceptive tolerance and heroin self-administration behavior.
Wang YJ; Tao YM; Li FY; Wang YH; Xu XJ; Chen J; Cao YL; Chi ZQ; Neumeyer JL; Zhang A; Liu JG
J Pharmacol Exp Ther; 2009 Apr; 329(1):306-13. PubMed ID: 19136637
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological characterization and therapeutic potential for the treatment of opioid abuse with ATPM-ET, an N-ethyl substituted aminothiazolomorphinan with κ agonist and μ agonist/antagonist activity.
Sun JF; Wang YH; Chai JR; Li FY; Hang A; Lu G; Tao YM; Cheng Y; Chi ZQ; Neumeyer JL; Zhang A; Liu JG; Wang YJ
Eur J Pharmacol; 2014 Oct; 740():455-63. PubMed ID: 24998879
[TBL] [Abstract][Full Text] [Related]
3. Effects of ATPM-ET, a novel κ agonist with partial μ activity, on physical dependence and behavior sensitization in mice.
SUN JF; WANG YH; LI FY; LU G; TAO YM; CHENG Y; CHEN J; XU XJ; CHI ZQ; NEUMEYER JL; ZHANG A; LIU JG
Acta Pharmacol Sin; 2010 Dec; 31(12):1547-52. PubMed ID: 21102484
[TBL] [Abstract][Full Text] [Related]
4. Heterologous mu-opioid receptor adaptation by repeated stimulation of kappa-opioid receptor: up-regulation of G-protein activation and antinociception.
Narita M; Khotib J; Suzuki M; Ozaki S; Yajima Y; Suzuki T
J Neurochem; 2003 Jun; 85(5):1171-9. PubMed ID: 12753076
[TBL] [Abstract][Full Text] [Related]
5. Functional interaction among opioid receptor types: up-regulation of mu- and delta-opioid receptor functions after repeated stimulation of kappa-opioid receptors.
Khotib J; Narita M; Suzuki M; Yajima Y; Suzuki T
Neuropharmacology; 2004 Mar; 46(4):531-40. PubMed ID: 14975677
[TBL] [Abstract][Full Text] [Related]
6. Dextromethorphan and ketamine potentiate the antinociceptive effects of mu- but not delta- or kappa-opioid agonists in a mouse model of acute pain.
Baker AK; Hoffmann VL; Meert TF
Pharmacol Biochem Behav; 2002 Dec; 74(1):73-86. PubMed ID: 12376154
[TBL] [Abstract][Full Text] [Related]
7. Long-term voluntary access to running wheels decreases kappa-opioid antinociception.
D'Anci KE; Gerstein AV; Kanarek RB
Pharmacol Biochem Behav; 2000 Jun; 66(2):343-6. PubMed ID: 10880688
[TBL] [Abstract][Full Text] [Related]
8. The novel kappa-opioid receptor agonist TRK-820 has no affect on the development of antinociceptive tolerance to morphine in mice.
Tsuji M; Yamazaki M; Takeda H; Matsumiya T; Nagase H; Tseng LF; Narita M; Suzuki T
Eur J Pharmacol; 2000 Apr; 394(1):91-5. PubMed ID: 10771039
[TBL] [Abstract][Full Text] [Related]
9. Effects of ACEA-1328, a NMDA receptor/glycine site antagonist, on U50,488H-induced antinociception and tolerance.
Lutfy K; Doan P; Nguyen M; Weber E
Eur J Pharmacol; 1999 Nov; 384(1):1-5. PubMed ID: 10611412
[TBL] [Abstract][Full Text] [Related]
10. Characterization of a novel bivalent morphinan possessing kappa agonist and micro agonist/antagonist properties.
Mathews JL; Peng X; Xiong W; Zhang A; Negus SS; Neumeyer JL; Bidlack JM
J Pharmacol Exp Ther; 2005 Nov; 315(2):821-7. PubMed ID: 16076937
[TBL] [Abstract][Full Text] [Related]
11. Characterization of the antinociceptive effect of oxycodone in male and female rats.
Holtman JR; Wala EP
Pharmacol Biochem Behav; 2006 Jan; 83(1):100-8. PubMed ID: 16434089
[TBL] [Abstract][Full Text] [Related]
12. Morphine can produce analgesia via spinal kappa opioid receptors in the absence of mu opioid receptors.
Yamada H; Shimoyama N; Sora I; Uhl GR; Fukuda Y; Moriya H; Shimoyama M
Brain Res; 2006 Apr; 1083(1):61-9. PubMed ID: 16530171
[TBL] [Abstract][Full Text] [Related]
13. L-type and T-type calcium channel blockade potentiate the analgesic effects of morphine and selective mu opioid agonist, but not to selective delta and kappa agonist at the level of the spinal cord in mice.
Doğrul A; Yeşilyurt Ö; Işmer A; Güzeldemir EM
Pain; 2001 Jul; 93(1):61-68. PubMed ID: 11406339
[TBL] [Abstract][Full Text] [Related]
14. Functional effects of systemically administered agonists and antagonists of mu, delta, and kappa opioid receptor subtypes on body temperature in mice.
Baker AK; Meert TF
J Pharmacol Exp Ther; 2002 Sep; 302(3):1253-64. PubMed ID: 12183687
[TBL] [Abstract][Full Text] [Related]
15. Dextromethorphan differentially affects opioid antinociception in rats.
Chen SL; Huang EY; Chow LH; Tao PL
Br J Pharmacol; 2005 Feb; 144(3):400-4. PubMed ID: 15655510
[TBL] [Abstract][Full Text] [Related]
16. Chronic muscle pain induced by repeated acid Injection is reversed by spinally administered mu- and delta-, but not kappa-, opioid receptor agonists.
Sluka KA; Rohlwing JJ; Bussey RA; Eikenberry SA; Wilken JM
J Pharmacol Exp Ther; 2002 Sep; 302(3):1146-50. PubMed ID: 12183674
[TBL] [Abstract][Full Text] [Related]
17. Blockade of mu-opioid receptor-mediated G-protein activation and antinociception by TRK-820 in mice.
Mizoguchi H; Hung KC; Leitermann R; Narita M; Nagase H; Suzuki T; Tseng LF
Eur J Pharmacol; 2003 Feb; 461(1):35-9. PubMed ID: 12568913
[TBL] [Abstract][Full Text] [Related]
18. Administration of mu-, kappa- or delta2-receptor agonists via osmotic minipumps suppresses murine splenic antibody responses.
Rahim RT; Meissler JJ; Cowan A; Rogers TJ; Geller EB; Gaughan J; Adler MW; Eisenstein TK
Int Immunopharmacol; 2001 Oct; 1(11):2001-9. PubMed ID: 11606031
[TBL] [Abstract][Full Text] [Related]
19. Effect of repeated administration of TRK-820, a kappa-opioid receptor agonist, on tolerance to its antinociceptive and sedative actions.
Suzuki T; Izumimoto N; Takezawa Y; Fujimura M; Togashi Y; Nagase H; Tanaka T; Endoh T
Brain Res; 2004 Jan; 995(2):167-75. PubMed ID: 14672806
[TBL] [Abstract][Full Text] [Related]
20. Interactions of cocaine with morphine, U-50,488H and [D-Pen2, D-Pen5]enkaphalin.
Bhargava HN; Cao YJ
Peptides; 1998; 19(3):563-8. PubMed ID: 9533646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
